Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
Hjerpe E, Staf C, Dahm-Kähler P, Stålberg K, Bjurberg M, Holmberg E, Borgfeldt C, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E. Hjerpe E, et al. Acta Oncol. 2018 Mar;57(3):331-337. doi: 10.1080/0284186X.2017.1400691. Epub 2017 Nov 12. Acta Oncol. 2018. PMID: 29130381
Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study.
Stålberg K, Bjurberg M, Borgfeldt C, Carlson J, Dahm-Kähler P, Flöter-Rådestad A, Hellman K, Hjerpe E, Holmberg E, Kjølhede P, Marcickiewicz J, Rosenberg P, Tholander B, Åvall-Lundqvist E, Högberg T. Stålberg K, et al. Among authors: hjerpe e. Acta Oncol. 2019 Nov;58(11):1628-1633. doi: 10.1080/0284186X.2019.1643036. Epub 2019 Aug 2. Acta Oncol. 2019. PMID: 31373248
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K. Moyano-Galceran L, et al. Among authors: hjerpe e. EMBO Mol Med. 2020 Apr 7;12(4):e11177. doi: 10.15252/emmm.201911177. Epub 2020 Mar 2. EMBO Mol Med. 2020. PMID: 32115889 Free PMC article.
Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.
Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, Shi Y, Saei AA, Visnes T, Lindström MS, Rihani A, Moyano-Galceran L, Carlson JW, Hjerpe E, Joneborg U, Lehti K, Hartman J, Helleday T, Zubarev R, Selivanova G. Peuget S, et al. Among authors: hjerpe e. Cancer Res. 2020 Apr 1;80(7):1538-1550. doi: 10.1158/0008-5472.CAN-19-2069. Epub 2020 Feb 4. Cancer Res. 2020. PMID: 32019870
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P, Holmberg E, Holtenman M, Rådestad AF, Borgfeldt C, Hjerpe E, Marcickiewicz J, Bjurberg M, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E, Stålberg K. Dahm-Kähler P, et al. Among authors: hjerpe e. Gynecol Oncol. 2021 Apr;161(1):244-250. doi: 10.1016/j.ygyno.2021.01.012. Epub 2021 Feb 10. Gynecol Oncol. 2021. PMID: 33581846
HSP60 predicts survival in advanced serous ovarian cancer.
Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E. Hjerpe E, et al. Int J Gynecol Cancer. 2013 Mar;23(3):448-55. doi: 10.1097/IGC.0b013e318284308b. Int J Gynecol Cancer. 2013. PMID: 23429486
23 results